Educational Risk Minimisation Materials for Keytruda (pembrolizumab) 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion -

Educational Risk Minimisation Materials for Keytruda (pembrolizumab) 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion
Information type: Safety alerts
Source: Merck Sharp and Dohme
Specialities: Neurological disorders
Summary
This document contains key information to help minimise risk of immune-mediated side-effects such as immune-related pneumonitis, colitis, hepatitis, nephritis, endocrinopathies and other immune-related adverse reactions, providing guidance on how to monitor and manage them.
UKMi comment
Document also draws attention to the availability of the Patient Information Brochure and Patient Alert Card.
Related links: Brochure Patient Alert Card